MIRA Pharmaceuticals (NASDAQ:MIRA) | WebDisclosure

Basculer en Français

9864	Companies
198258	Keywords
129309	Articles
105439	Press releases

Home
Companies
MIRA Pharmaceuticals

PRESS RELEASE

published on 11/20/2024 at 13:44, 1 year 2 months ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site
MIRA Pharmaceuticals progresses towards clinical-stage status with Phase I/IIa trial announcement on Ketamir-2, a novel oral ketamine analog, for pain management. CHDR's PainCart technology leveraged

Pain Management MIRA Pharmaceuticals Ketamir-2 Clinical-stage Company Phase I/IIa Trial
BRIEF

published on 10/28/2024 at 12:35, 1 year 3 months ago

MIRA Pharmaceuticals Reveals Promising Preclinical Results for Ketamir-2

Preclinical Results MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain FDA Designation
BRIEF

published on 10/28/2024 at 12:35, 1 year 3 months ago

MIRA Pharmaceuticals révèle des résultats précliniques prometteurs pour le kétamir-2

Résultats Précliniques Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Désignation De La FDA
PRESS RELEASE

published on 10/28/2024 at 12:30, 1 year 3 months ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a potential breakthrough therapy surpassing current treatments. Study shows 60% greater efficacy than gabapentin in reducing chemotherapy-induced pain, to be presented at Pain Therapeutics Summit

Pain Management Preclinical Results MIRA Pharmaceuticals Ketamir-2 Breakthrough Therapy
BRIEF

published on 10/21/2024 at 13:35, 1 year 3 months ago

MIRA Pharmaceuticals Introduces Ketamir-2 as a Promising Pain Relief Alternative

Preclinical Study MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Gabapentin And Pregabalin
BRIEF

published on 10/21/2024 at 13:35, 1 year 3 months ago

MIRA Pharmaceuticals présente le kétamir-2 comme une alternative prometteuse au traitement de la douleur

Étude Préclinique Ketamir-2 Douleur Neuropathique MIRA Pharmaceutique Gabapentine Et Prégabaline
PRESS RELEASE

published on 10/21/2024 at 13:30, 1 year 3 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
MIRA Pharmaceuticals, Inc. announces promising results for novel oral ketamine analog Ketamir-2 in providing superior pain relief compared to current treatments. Preparing for Phase 1 clinical trials and exploring potential in PTSD

Clinical Trials PTSD MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain
BRIEF

published on 09/27/2024 at 13:35, 1 year 4 months ago

MIRA Pharmaceuticals Reveals New Data on Ketamir-2 at Annual Pain Therapeutics Summit

Preclinical Data MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Pain Therapeutics Summit
BRIEF

published on 09/27/2024 at 13:35, 1 year 4 months ago

MIRA Pharmaceuticals dévoile de nouvelles données sur le kétamir-2 lors du sommet annuel sur les thérapies contre la douleur

Ketamir-2 Données Précliniques Douleur Neuropathique MIRA Pharmaceutique Sommet Sur Les Thérapies Contre La Douleur
PRESS RELEASE

published on 09/27/2024 at 13:30, 1 year 4 months ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
MIRA Pharmaceuticals presents preclinical results at Pain Therapeutics Summit showcasing that Ketamir-2 achieves 100% reversal of neuropathic pain. The innovative therapy targets NMDA receptors for enhanced efficacy

Preclinical Results MIRA Pharmaceuticals Ketamir-2 NMDA Receptor Neuropathic Pain

Accesswire

Published on 02/14/2026 at 01:00, 14 hours 58 minutes ago

Orogen Royalties Announces Annual Equity Compensation Grant
Published on 02/13/2026 at 22:30, 17 hours 28 minutes ago

Norse Gold Corp. Announces New Director
Published on 02/13/2026 at 22:15, 17 hours 43 minutes ago

Storm Completes Sale of Miminiska Project for $5.8M and Outlines Plans for 2026
Published on 02/13/2026 at 17:45, 22 hours 13 minutes ago

Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 1 day 1 hour ago

Datametrex Received $500,000 Purchase Order For Data Centre Solutions

View all ACCESSWIRE

EQS Group

Published on 02/14/2026 at 06:05, 9 hours 52 minutes ago

The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
Published on 02/13/2026 at 19:20, 20 hours 38 minutes ago

Retail offering successfully completed and update on Euronext Growth Oslo listing
Published on 02/13/2026 at 19:01, 20 hours 56 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/13/2026 at 18:20, 21 hours 37 minutes ago

GLOBAL TECHNOLOGY LEADERS LAUNCH TRUSTED TECH ALLIANCE
Published on 02/13/2026 at 18:07, 21 hours 50 minutes ago

EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range

Les Echos

Published on 02/14/2026 at 07:00, 8 hours 58 minutes ago

Groupe DLSI - Chiffre d'affaires 2025
Published on 02/13/2026 at 18:05, 21 hours 53 minutes ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 21 hours 53 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 22 hours 8 minutes ago

Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 22 hours 8 minutes ago

Nombre total d'actions et droits de vote - janvier 2026

View all LES ECHOS COMFI WIRE